Cargando…
Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis
INTRODUCTION: The phosphodiesterase 4 (PDE4) inhibitor, rolipram, has beneficial effects on tissue inflammation, injury and fibrosis, including in the liver. Since rolipram elicits significant CNS side-effects in humans (ie, nausea and emesis), our group developed a fusogenic lipid vesicle (FLV) dru...
Autores principales: | Gobejishvili, Leila, Rodriguez, Walter E, Bauer, Philip, Wang, Yali, Soni, Chirag, Lydic, Todd, Barve, Shirish, McClain, Craig, Maldonado, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078351/ https://www.ncbi.nlm.nih.gov/pubmed/35535222 http://dx.doi.org/10.2147/DDDT.S355796 |
Ejemplares similares
-
cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease
por: Elnagdy, Mohamed, et al.
Publicado: (2020) -
Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies
por: Montoya-Durango, Diego, et al.
Publicado: (2023) -
Focus on the Liver: Alcohol Use, Highly Active Antiretroviral Therapy, and Liver Disease In HIV-Infected Patients
por: Barve, Shirish, et al.
Publicado: (2010) -
Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury
por: Donde, Hridgandh, et al.
Publicado: (2019) -
Jumonji: Welcome to the World of Interferon Signaling in Alcohol and HCV
por: Moghe, Akshata, et al.
Publicado: (2017)